Brindley A
AstraZeneca R&D Charnwood, Leicestershire, United Kingdom.
J Allergy Clin Immunol. 1999 Dec;104(6):S221-6. doi: 10.1016/s0091-6749(99)70034-5.
The phase out of chlorofluorocarbon (CFC) propellants has necessitated the reformulation of pressurized metered dose inhalers (pMDIs) with hydrofluoroalkane (HFA) propellants. One of the main challenges has been that conventional surfactants used for CFC-based pMDIs were not soluble in HFAs. Since one of the main aims of a pMDI is to deliver a reproducible dose of medication to the patient, it is vital that, for suspension-type pMDI formulations, the suspension is stabilized sufficiently for a reproducible dose to be delivered. A new technique has been developed that measures suspension stability more objectively than before. This technique, optical suspension characterization, was used to compare the performance of different formulations of respiratory drugs in HFAs. The optical suspension characterization data were correlated with conventional analytic techniques for the determination of the stability of the suspension formulation.
淘汰氯氟烃(CFC)推进剂使得用氢氟烷烃(HFA)推进剂重新配制压力定量吸入器(pMDI)成为必要。主要挑战之一是用于基于CFC的pMDI的传统表面活性剂不溶于HFA。由于pMDI的主要目标之一是向患者提供可重复剂量的药物,对于混悬型pMDI制剂而言,至关重要的是,混悬液要得到充分稳定,以便能够提供可重复的剂量。已开发出一种新技术,该技术比以往更客观地测量混悬液稳定性。这种技术,即光学混悬液表征,被用于比较HFA中不同呼吸道药物制剂的性能。光学混悬液表征数据与用于确定混悬液制剂稳定性的传统分析技术相关联。